Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Co., has entered into an agreement with Inovalon, a technology provider of cloud-based platforms for the life sciences. The agreement utilizes Inovalon and Avalere’s combined platform aimed at supporting greater customer insight, data integration and analytics, and provider and patient-level intervention capabilities. This aims to support outcomes-based contracting and help translate clinical outcomes into real world ...